BQ-3020

Product Name:BQ-3020

CAS No:143113-45-5

Purity:95%

Molar Mass:2006.35

Chemical Formula:C96H140N20O25S

Storage:Store at -20 degrees Celsius

Sequence:LMDKEAVYFAHLDIIW

Target:ETB

Application:

BQ-3020 is a synthetic peptide that acts as a highly selective agonist for the endothelin B (ETB) receptor. It is structurally designed to mimic the natural endothelin peptides, which are involved in various physiological processes, including vasoconstriction, vasodilation, and regulation of blood pressure. BQ-3020's selective action on the ETB receptor makes it a valuable tool in cardiovascular research, particularly in studies focusing on the roles of endothelins in blood vessel function, renal physiology, and the pathophysiology of diseases such as hypertension, heart failure, and pulmonary arterial hypertension. Its specificity also aids in exploring therapeutic potentials for conditions associated with endothelin dysregulation

Current Research:

BQ-3020 (CAS: 143113-45-5) is a synthetic, linear peptide analog of endothelin-1 (ET-1), specifically designed to act as a highly potent and selective agonist for the endothelin B (ET_B) receptor. Its amino acid sequence is Ac-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp, with N-terminal acetylation enhancing its receptor affinity. Pharmacological Profile: Receptor Selectivity: BQ-3020 exhibits a high affinity for the human ET_B receptor, with a dissociation constant (K_i) of approximately 0.18 nM, while showing significantly lower affinity for the endothelin A (ET_A) receptor, with a K_i of about 970 nM. Functional Activity: As an ET_B receptor agonist, BQ-3020 mimics the effects of endogenous endothelins by inducing vasodilation and promoting the clearance of endothelin peptides from the circulation. Its selectivity allows for targeted activation of ET_B receptors without significant activation of ET_A receptors, which are primarily associated with vasoconstriction. Research Applications: BQ-3020 serves as a valuable tool in cardiovascular research, particularly in studies investigating the distinct roles of endothelin receptor subtypes. Its selective activation of ET_B receptors enables researchers to delineate the physiological and pathological functions of these receptors in vascular tone regulation, endothelial function, and related disease states. Handling and Storage: For laboratory use, BQ-3020 is typically supplied as a lyophilized powder with a purity of greater than 95%. It is recommended to store the compound at -20 degrees Celsius, protected from light, to maintain its stability and bioactivity. Safety Considerations: BQ-3020 is classified as an acute toxicant via oral and inhalation routes. Appropriate safety measures, including the use of personal protective equipment and proper laboratory ventilation, should be implemented to minimize exposure risks. In summary, BQ-3020 is a potent and selective ET_B receptor agonist extensively utilized in research to explore endothelin-mediated physiological processes and their implications in cardiovascular health and disease.

Reference:

Strachan, F. E., Crockett, T. R., Mills, N. L., Gray, G. A., & Webb, D. J. (2000). Constriction to ETB receptor agonists, BQ‐3020 and sarafotoxin S6c, in human resistance and capacitance vessels in vivo. British journal of clinical pharmacology, 50(1), 27-30.